229 related articles for article (PubMed ID: 24725025)
1. Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease.
Ferla R; Claudiani P; Cotugno G; Saccone P; De Leonibus E; Auricchio A
Hum Gene Ther; 2014 Jul; 25(7):609-18. PubMed ID: 24725025
[TBL] [Abstract][Full Text] [Related]
2. Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.
Alliegro M; Ferla R; Nusco E; De Leonibus C; Settembre C; Auricchio A
Mol Ther; 2016 Dec; 24(12):2054-2063. PubMed ID: 27658524
[TBL] [Abstract][Full Text] [Related]
3. Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey.
Kılıç M; Dursun A; Coşkun T; Tokatlı A; Özgül RK; Yücel-Yılmaz D; Karaca M; Doğru D; Alehan D; Kadayıfçılar S; Genç A; Turan-Dizdar H; Gönüldaş B; Savcı S; Sağlam M; Aksoy C; Arslan U; Sivri HS
Am J Med Genet A; 2017 Nov; 173(11):2954-2967. PubMed ID: 28884960
[TBL] [Abstract][Full Text] [Related]
4. CNS-directed gene therapy for lysosomal storage diseases.
Sands MS; Haskins ME
Acta Paediatr; 2008 Apr; 97(457):22-7. PubMed ID: 18339183
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle.
Tessitore A; Faella A; O'Malley T; Cotugno G; Doria M; Kunieda T; Matarese G; Haskins M; Auricchio A
Mol Ther; 2008 Jan; 16(1):30-7. PubMed ID: 17955027
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8.
Ferla R; O'Malley T; Calcedo R; O'Donnell P; Wang P; Cotugno G; Claudiani P; Wilson JM; Haskins M; Auricchio A
Hum Gene Ther; 2013 Feb; 24(2):163-9. PubMed ID: 23194248
[TBL] [Abstract][Full Text] [Related]
7. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.
Roca C; Motas S; Marcó S; Ribera A; Sánchez V; Sánchez X; Bertolin J; León X; Pérez J; Garcia M; Villacampa P; Ruberte J; Pujol A; Haurigot V; Bosch F
Hum Mol Genet; 2017 Apr; 26(8):1535-1551. PubMed ID: 28334745
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for lysosomal storage diseases (LSDs) in large animal models.
Haskins M
ILAR J; 2009; 50(2):112-21. PubMed ID: 19293456
[TBL] [Abstract][Full Text] [Related]
9. Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.
Simonis H; Yaghootfam C; Sylvester M; Gieselmann V; Matzner U
Hum Mol Genet; 2019 Jun; 28(11):1810-1821. PubMed ID: 30657900
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for lysosomal storage disorders.
Barranger JM; Novelli EA
Expert Opin Biol Ther; 2001 Sep; 1(5):857-67. PubMed ID: 11728220
[TBL] [Abstract][Full Text] [Related]
11. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer.
Cotugno G; Annunziata P; Tessitore A; O'Malley T; Capalbo A; Faella A; Bartolomeo R; O'Donnell P; Wang P; Russo F; Sleeper MM; Knox VW; Fernandez S; Levanduski L; Hopwood J; De Leonibus E; Haskins M; Auricchio A
Mol Ther; 2011 Mar; 19(3):461-9. PubMed ID: 21119624
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
13. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors.
Liu G; Martins I; Wemmie JA; Chiorini JA; Davidson BL
J Neurosci; 2005 Oct; 25(41):9321-7. PubMed ID: 16221840
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
Biffi A
Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lysosomal storage diseases: recent patents and future strategies.
Ortolano S; Viéitez I; Navarro C; Spuch C
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
[TBL] [Abstract][Full Text] [Related]
17. A Clinical Trial of Gene Therapy for Mucopolysaccharidosis VI, a Severe Lysosomal Storage Disorder (MeuSIX).
Hum Gene Ther Clin Dev; 2015 Jun; 26(2):86-8. PubMed ID: 26086756
[No Abstract] [Full Text] [Related]
18. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.
Penati R; Fumagalli F; Calbi V; Bernardo ME; Aiuti A
J Inherit Metab Dis; 2017 Jul; 40(4):543-554. PubMed ID: 28560469
[TBL] [Abstract][Full Text] [Related]
19. [Application of adeno-associated virus-mediated gene therapy in lysosomal storage diseases].
Lin XQ; Wang XL; Peng J
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1281-1287. PubMed ID: 36398557
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
